- Patent Title: Anti-GCC antibody molecules and related compositions and methods
-
Application No.: US16029101Application Date: 2018-07-06
-
Publication No.: US10941211B2Publication Date: 2021-03-09
- Inventor: Samuel S. Nam , Edward A. Greenfield , John S. Babcook , Theresa O'Keefe , Shixin Qin
- Applicant: Millennium Pharmaceuticals, Inc. , Amgen British Columbia Inc.
- Applicant Address: US MA Cambridge; CA Burnaby
- Assignee: Millennium Pharmaceuticals, Inc.,Amgen British Columbia Inc.
- Current Assignee: Millennium Pharmaceuticals, Inc.,Amgen British Columbia Inc.
- Current Assignee Address: US MA Cambridge; CA Burnaby
- Agency: Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
- Main IPC: C07K16/40
- IPC: C07K16/40 ; C07K16/30 ; A61K47/68 ; A61P35/00 ; A61K39/395 ; G01N33/573 ; A61K39/00

Abstract:
Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. The antibodies bind an extracellular domain of GCC and can be internalized. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.
Public/Granted literature
- US20180355062A1 ANTI-GCC ANTIBODY MOLECULES AND RELATED COMPOSITIONS AND METHODS Public/Granted day:2018-12-13
Information query